Hi Market Makers,
 

Power Hour
 

Indaptus Therapeutics, Inc. (Nasdaq: INDP) is having an incredible day in the market, with shares surging on the back of groundbreaking news and strong financials. Today’s stellar performance, marked by a significant jump post-open, has everyone wondering: Are we going to see an even stronger finish? With continuous breakthroughs and increasing interest, Indaptus Therapeutics is the company to watch right now! (2)(3)(4)(5)
 

🔑 Key Developments:
 

📗 Strong Financials: Indaptus reported a decrease in research and development expenses by 15%, and general and administrative expenses by 9% for Q1 2024. As of March 31, 2024, the company had cash and cash equivalents of $9.7 million, demonstrating efficient management and a clear focus on advancing their clinical programs. (2)(3)(4)
 

📊Robust Market Potential: According to two Wall Street analysts, the price target for Indaptus Therapeutics, Inc. (Nasdaq: INDP) ranges between $8.00 and $12.00, with an average price target of $10.00. This represents a potential ~300% increase from the current price of $2.48! (1)(2)
 

😎 Innovative Approach: Indaptus is pioneering a unique “Pulse-Prime” immuno-oncology therapy with its lead clinical candidate, Decoy20. This novel therapy targets a broad range of cancers including liver, pancreatic, colorectal, and non-small cell lung. (2)(3)(4)
 

📺 Strategic Presentations: Over the weekend on Saturday, June 1 Indaptus presented a poster on the preliminary results of Decoy20 at the American Society of Clinical Oncology (ASCO) annual meeting, highlighting its first-in-class potential across a diverse range of cancers. (2)(3)(4)
 

💡 Why Indaptus Stands Out:
 

• Decoy20’s Unique Mechanism: Composed of attenuated and killed Gram-negative bacteria, Decoy20 activates both innate and adaptive immune systems, targeting tumors without inducing excessive toxicity. This innovative approach is designed to trick the body into launching a broad antitumor response. (2)(3)(4)
 

• Broad Applications: Beyond cancer, Decoy20 has shown significant single-agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in preclinical models. (2)(3)(4)
 

• Positive Momentum: Indaptus continues to build on its strong clinical evidence, with presentations at major conferences like AACR and ASCO(They just did!), further validating its promising results and potential impact on cancer treatment. (2)(3)(4)(5)
 

👀 Ready for the Next Big Thing? 
 

Keep a sharp eye on Indaptus Therapeutics, Inc. (Nasdaq: INDP). Their groundbreaking work in immunotherapy and strong market potential make them THE company to watch.
 

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://www.tipranks.com/stocks/indp/forecast
2. https://finance.yahoo.com/quote/INDP/
3. https://finance.yahoo.com/news/indaptus-therapeutics-announces-completion-first-120000009.html
4. https://finance.yahoo.com/news/indaptus-therapeutics-reports-first-quarter-120000721.html

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and Legends Media LLC, Momentum Media LLC has been hired for a period beginning on 06/02/2024 and ending on 06/03/2024 to publicly disseminate information about (INDP:US) via digital communications. We have been paid fourteen thousand five hundred dollars USD. We own zero shares of (INDP:US)